Daniel E. Cohen

4.6k total citations
55 papers, 1.6k citations indexed

About

Daniel E. Cohen is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Daniel E. Cohen has authored 55 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hepatology, 32 papers in Epidemiology and 21 papers in Infectious Diseases. Recurrent topics in Daniel E. Cohen's work include Hepatitis C virus research (49 papers), Liver Disease Diagnosis and Treatment (23 papers) and Hepatitis B Virus Studies (22 papers). Daniel E. Cohen is often cited by papers focused on Hepatitis C virus research (49 papers), Liver Disease Diagnosis and Treatment (23 papers) and Hepatitis B Virus Studies (22 papers). Daniel E. Cohen collaborates with scholars based in United States, Germany and France. Daniel E. Cohen's co-authors include Thomas Podsadecki, Barry Bernstein, Eric Lawitz, Edward Tam, Rajeev Menon, Lois Larsen, Kris V. Kowdley, Fred Poordad, Mark Sulkowski and Rakesh Tripathi and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and PLoS ONE.

In The Last Decade

Daniel E. Cohen

54 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel E. Cohen United States	19	1.4k	1.3k	491	111	76	55	1.6k
Anu Osinusi United States	23	1.6k 1.1×	1.4k 1.1×	618 1.3×	137 1.2×	117 1.5×	86	2.0k
Janice Wahl United States	23	2.4k 1.6×	1.9k 1.5×	914 1.9×	163 1.5×	82 1.1×	66	2.5k
Federico Mensa United States	20	1.8k 1.2×	1.4k 1.1×	662 1.3×	167 1.5×	44 0.6×	88	1.9k
Philippe J. Zamor United States	11	944 0.7×	781 0.6×	311 0.6×	65 0.6×	72 0.9×	21	1.1k
Nathalie Adda United States	18	2.0k 1.4×	1.8k 1.4×	685 1.4×	181 1.6×	133 1.8×	55	2.3k
Vilma Sniukiene United States	15	2.3k 1.6×	2.0k 1.6×	510 1.0×	233 2.1×	108 1.4×	39	2.6k
Lois Larsen United States	24	2.0k 1.4×	1.8k 1.4×	612 1.2×	137 1.2×	171 2.3×	54	2.7k
Manuel García–Bengoechea Spain	9	950 0.7×	892 0.7×	237 0.5×	62 0.6×	49 0.6×	15	1.2k
Sarah Arterburn United States	19	2.3k 1.6×	2.3k 1.8×	398 0.8×	52 0.5×	53 0.7×	47	2.7k
Shelley George United States	11	2.0k 1.4×	1.7k 1.4×	510 1.0×	232 2.1×	103 1.4×	32	2.1k

Countries citing papers authored by Daniel E. Cohen

Since Specialization

Citations

This map shows the geographic impact of Daniel E. Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Cohen more than expected).

Fields of papers citing papers by Daniel E. Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel E. Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Cohen. The network helps show where Daniel E. Cohen may publish in the future.

Co-authorship network of co-authors of Daniel E. Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel E. Cohen. A scholar is included among the top collaborators of Daniel E. Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel E. Cohen. Daniel E. Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alami, Negar Niki, David C. Carter, Nisha V. Kwatra, et al.. (2023). A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity. PLoS neglected tropical diseases. 17(7). e0011392–e0011392. 3 indexed citations

Zha, Jiuhong, et al.. (2022). Effects of a ritonavir‐containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects. Pharmacology Research & Perspectives. 10(6). e01024–e01024. 2 indexed citations

Poordad, Fred, Armen Asatryan, Humberto Aguilar, et al.. (2020). Long‐term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ‐I and TOPAZ‐II trials. Journal of Viral Hepatitis. 27(5). 497–504. 12 indexed citations

Fuchs, Michael, Alexander Monto, Norbert Bräu, et al.. (2019). Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders. Journal of Medical Virology. 92(12). 3459–3464. 1 indexed citations

Menon, Rajeev, Amit Khatri, Hong Li, et al.. (2018). Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials. European Journal of Clinical Pharmacology. 75(2). 207–216. 6 indexed citations

Lawitz, Eric, Edward Gane, E. Cohen, et al.. (2018). Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease. Kidney International Reports. 4(2). 257–266. 17 indexed citations

Vasanthakumar, Aparna, J. Wade Davis, Manal Abunimeh, et al.. (2018). Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens. PLoS ONE. 13(5). e0198296–e0198296. 2 indexed citations

Cohen, E., et al.. (2017). Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials. Infectious Diseases and Therapy. 6(4). 515–529. 21 indexed citations

Rockstroh, Jürgen K., Jordan J. Feld, Stéphane Chevaliez, et al.. (2017). HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. Journal of Virological Methods. 245. 14–18. 28 indexed citations

10.

Polepally, Akshanth R., Haoyu Wang, Patrick Marroum, et al.. (2017). Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection. The AAPS Journal. 19(5). 1523–1535. 1 indexed citations

11.

Welzel, Tania M., Tarik Asselah, Emily O. Dumas, et al.. (2017). Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. The Lancet. Gastroenterology & hepatology. 2(7). 494–500. 33 indexed citations

12.

Pockros, Paul J., K. Rajender Reddy, Parvez Mantry, et al.. (2016). Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. Gastroenterology. 150(7). 1590–1598. 197 indexed citations

13.

Lalezari, Jacob, Peter Varunok, Kris V. Kowdley, et al.. (2015). Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. Journal of Hepatology. 63(2). 364–369. 88 indexed citations

14.

Colombo, Massimo, Ola Weiland, Daniel E. Cohen, et al.. (2014). SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin. Hepatology. 60. 2 indexed citations

15.

Cloherty, Gavin, Daniel E. Cohen, Christoph Sarrazin, et al.. (2014). HCV RNA Assay Sensitivity Impacts the Management of Patients Treated with Direct-Acting Antivirals. Antiviral Therapy. 20(2). 177–183. 15 indexed citations

16.

Kowdley, Kris V., Eric Lawitz, Fred Poordad, et al.. (2014). Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1. New England Journal of Medicine. 370(3). 222–232. 185 indexed citations

17.

Lawitz, Eric, Fred Poordad, Kris V. Kowdley, et al.. (2013). A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. Journal of Hepatology. 59(1). 18–23. 55 indexed citations

18.

Cohen, Daniel E., Christopher J. Russell, Sarit A. Golub, & Kenneth H. Mayer. (2006). Prevalence of Hepatitis C Virus Infection among Men Who Have Sex with Men at a Boston Community Health Center and Its Association with Markers of High-Risk Behavior. AIDS Patient Care and STDs. 20(8). 557–564. 27 indexed citations

19.

Grover, Frederick L., et al.. (1990). A458 Intracranial Air Embolism Is Detected By The Transcranial Dopplcr (TCD) During Cardiopulmonary Bypass Procedures. Anesthesiology. 73(3A). NA–NA. 4 indexed citations

20.

Cohen, Daniel E., et al.. (1990). Bipolar components for severe periacetabular bone loss around the failed total hip arthroplasty.. PubMed. 113–8. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact